| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death
|
Bialik, Shani
|
|
2004
|
14 |
4 |
p. 283-294
12 p.
|
artikel
|
| 2 |
In search of drug treatment for genetic defects in the DNA damage response: the example of ataxia-telangiectasia
|
Shiloh, Yosef
|
|
2004
|
14 |
4 |
p. 295-305
11 p.
|
artikel
|
| 3 |
Introduction: Signal transduction therapy—10 years later
|
Levitzki, A
|
|
2004
|
14 |
4 |
p. 219-221
3 p.
|
artikel
|
| 4 |
Manipulation of the tumor suppressor p53 for potentiating cancer therapy
|
Haupt, Susan
|
|
2004
|
14 |
4 |
p. 244-252
9 p.
|
artikel
|
| 5 |
Oncogenic growth factor receptors: implications for signal transduction therapy
|
Mosesson, Yaron
|
|
2004
|
14 |
4 |
p. 262-270
9 p.
|
artikel
|
| 6 |
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs
|
Kloog, Yoel
|
|
2004
|
14 |
4 |
p. 253-261
9 p.
|
artikel
|
| 7 |
RNA molecules as anti-cancer agents
|
Friedrich, Inbar
|
|
2004
|
14 |
4 |
p. 223-230
8 p.
|
artikel
|
| 8 |
Stress-activated protein kinases—tumor suppressors or tumor initiators?
|
Engelberg, David
|
|
2004
|
14 |
4 |
p. 271-282
12 p.
|
artikel
|
| 9 |
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate”
|
|
|
2004
|
14 |
4 |
p. 306-
1 p.
|
artikel
|
| 10 |
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate
|
Coutré, Steven
|
|
2004
|
14 |
4 |
p. 307-315
9 p.
|
artikel
|
| 11 |
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer
|
Nachmias, Boaz
|
|
2004
|
14 |
4 |
p. 231-243
13 p.
|
artikel
|
Tijdschrift beschrijving